Digital health companies DarioHealth Corp (NASDAQ: DRIO) and OneStep announced on Monday a strategic collaboration to integrate smartphone-based, clinical-grade fall risk assessment technology into Dario's multi-condition digital health platform. The partnership aims to deliver measurable return on investment for health plans by reducing falls and improving outcomes among high-risk populations, including those with obesity and Medicare Advantage members experiencing frailty and balance issues.
Under a signed Memorandum of Understanding, with a Master Services Agreement expected shortly, Dario will incorporate OneStep's FDA-listed motion analysis technology to provide proactive fall risk identification and education. The integration will enable at-risk users to access real-time insights that support fall prevention and reduce related healthcare costs.
Falls generate more than USD50bn annually in direct medical expenses in the US, according to the Centers for Disease Control and Prevention, with Medicare and Medicaid covering around 75% of the total. The US fall management market, valued at nearly USD200m in 2024, is projected to exceed USD300m by 2033, reflecting a compound annual growth rate of more than 5%.
DarioHealth provides a multi-condition platform for chronic disease management across diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.
OneStep's smartphone-based gait analysis technology delivers clinical mobility insights to support fall prevention and remote patient monitoring.
DarioHealth and OneStep partner to integrate fall risk technology into digital health platform
Renalytix submits CE Mark application for kidneyIntelX.dkd in Europe
Ocular Therapeutix prices USD475m common stock offering
Early, Evidence-Led Cardiovascular Care Strengthened in High-Risk MENA Regions
AstraZeneca launches online platform to expand patient access to medications
Avant Technologies enters joint venture to advance stem cell-based diabetes treatments
Innovent and Ollin report progress in development of OLN324 (IBI324)
Alteogen secures European Commission approval for aflibercept biosimilar EYLUXVI
Eli Lilly and Company's orforglipron outperforms oral semaglutide in Phase 3 ACHIEVE-3 trial
Ascletis presents ASC30 study results at EASD Annual Meeting
Kodiak reports positive APEX data for KSI-101 in macular edema secondary to inflammation
Renalytix signs collaboration agreement with Tempus AI to expand KidneyIntelX.dkd access
Diamyd Medical secures Eurasian patent for insulin-based antigen therapy in type 1 diabetes